Author

Reena S. Cecchini

Observed names: Cecchini, Reena S., R. Cecchini, R. S. Cecchini, R.S. Cecchini, Reena Cecchini, Reena S Cecchini

Institutions: University of Pittsburgh, NRG Oncology

Observed institutions: American Cancer Society, Fox Chase Cancer Center, National Institutes of Health, Allegheny Health Network, Kaiser Permanente, The University of Texas MD Anderson Cancer Center, University of British Columbia, University of California, Los Angeles, University of Pittsburgh, Allegheny General Hospital, Jewish General Hospital, Eastern Cooperative Oncology Group, Denver VA Medical Center, Magee-Womens Hospital, UPMC Presbyterian, Regional Cancer Center, Kaiser Permanente Vallejo Medical Center, UPMC Hillman Cancer Center, Colorado Cancer Research Program, University of Pittsburgh Medical Center, National Cancer Institute, Centre Hospitalier de l’Université de Montréal, NRG Oncology, NSABP Foundation, UCLA Jonsson Comprehensive Cancer Center, Kaiser Permanente Northern California, McGill University, UConn Health

ORCID: 0000-0002-9075-9357

Observed ORCID: 0000-0002-9075-9357

OpenAlex ID: A5006334177

Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

2005 · Bernard Fisher, Joseph P. Costantino, et al. · JNCI Journal of the National Cancer Institute · 1,341

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

2010 · Victor G. Vogel, Joseph P. Costantino, et al. · Cancer Prevention Research · 647

PDF

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

2019 · Frank A Vicini, Reena S Cecchini, et al. · The Lancet · 482

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

2019 · Louis Fehrenbacher, Reena S. Cecchini, et al. · Journal of Clinical Oncology · 404

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

2006 · Victor G. Vogel, Joseph P. Costantino, et al. · Obstetrical & Gynecological Survey · 329

Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07

2007 · Stephanie R. Land, Jacek A. Kopec, et al. · Journal of Clinical Oncology · 239

PDF

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

2015 · Richard G Margolese, Reena S Cecchini, et al. · The Lancet · 198

Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial

2011 · Patricia A. Ganz, Stephanie R. Land, et al. · Journal of Clinical Oncology · 133

PDF

Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials

2012 · Reena S. Cecchini, Joseph P. Costantino, et al. · Cancer Prevention Research · 111

Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial

2008 · Sandra M. Swain, Stephanie R. Land, et al. · Breast Cancer Research and Treatment · 108

Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01

2012 · Kelley M. Kidwell, Greg Yothers, et al. · Cancer · 96

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

2015 · Patricia A Ganz, Reena S Cecchini, et al. · The Lancet · 78

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2

2017 · Patricia A. Ganz, Edward H. Romond, et al. · Journal of Clinical Oncology · 70

PDF

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

2019 · Evandro de Azambuja, Noam Ponde, et al. · Breast Cancer Research and Treatment · 68

PDF

Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06

2007 · Jacek A. Kopec, Greg Yothers, et al. · Journal of Clinical Oncology · 68

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)

2011 · Carolyn D. Runowicz, Joseph P. Costantino, et al. · American Journal of Obstetrics and Gynecology · 63

PDF

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1

2012 · Eitan Amir, Reena S. Cecchini, et al. · Breast Cancer Research and Treatment · 53

PDF

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy

2025 · Jeremy Braybrooke, Rosie Bradley, et al. · The Lancet · 42

Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery

2020 · Mark Basik, Reena S Cecchini, et al. · Cancer Research · 42

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

2015 · Reena S. Cecchini, Sandra M. Swain, et al. · Cancer Epidemiology Biomarkers & Prevention · 40

Cosmetic Outcome from Post Lumpectomy Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 Phase III Clinical Trial

2019 · J.R. White, K. Winter, et al. · International Journal of Radiation Oncology*Biology*Physics · 38

PDF

The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer

2008 · D. Lawrence Wickerham, Joseph P. Costantino, et al. · Recent results in cancer research/Recent Results in Cancer Research · 38

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.

2022 · Julia R. White, Stewart J. Anderson, et al. · Journal of Clinical Oncology · 30

An Association Between Postoperative Radiotherapy for Primary Breast Cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) Studies and the Subsequent Appearance of Pleural Mesothelioma

2007 · Melvin Deutsch, Stephanie R. Land, et al. · American Journal of Clinical Oncology · 28

Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR)

2012 · Reena S. Cecchini, Joseph P. Costantino, et al. · Cancer Prevention Research · 27

Works count: 134

Citation count: 5,049

H-index: 25

I10-index: 37